Treatment outcome and safety of anti-PD-1 antibody against elderly non-small cell lung cancer.

被引：0
|
作者：
Sakatani, Toshio
Saihara, Aya
Ikushima, Hiroaki
Takeshima, Hideyuki
Taniguchi, Yuri
Hojo, Masayuki
Usui, Kazuhiro
机构：
[1] NTT Med Ctr Tokyo, Tokyo, Japan
[2] Kanto Med Ctr NTT EC, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e14249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14249
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy
    Kim, Eun Young
    Kim, Young Saing
    Park, Inkeun
    Ahn, Hee Kyung
    Lee, Hee Young
    Kim, Jeong Ho
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3930 - S3932
  • [22] Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
    Nishino, Mizuki
    Chambers, Emily S.
    Chong, Curtis R.
    Ramaiya, Nikhil H.
    Gray, Stacy W.
    Marcoux, J. Paul
    Hatabu, Hiroto
    Janne, Pasi A.
    Hodi, F. Stephen
    Awad, Mark M.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (04) : 289 - 293
  • [23] Anti-PD-1 antibody monotherapy or anti-PD-1 antibody combination with chemotherapy treated non-small cell lung cancer (NSCLC) patients with EGFR mutation: A retrospective analysis.
    Yu, Shaorong
    Hu, Ran
    Shi, Meiqi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Efficacy Impact of Serum VEGF for Elderly or Poor PS Patients Receiving Anti-PD-1 Antibody with Advanced Non-Small Cell Lung Cancer
    Shibaki, R.
    Murakami, S.
    Shinno, Y.
    Matsumoto, Y.
    Yoshida, T.
    Goto, Y.
    Kanda, S.
    Horinouchi, H.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S932 - S932
  • [25] Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report
    Xu, Shiting
    Shukuya, Takehito
    Shimamura, Shoko
    Hayashi, Takuo
    Sato, Yoshihiko
    Shiozaki, Hitomi
    Nishioki, Toshihiko
    Nishino, Koichi
    Kato, Motoyasu
    Hattori, Aritoshi
    Shimada, Naoko
    Suzuki, Kenji
    Kitano, Shigehisa
    Takahashi, Kazuhisa
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (03) : 666 - 672
  • [26] Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Su, Chaoyue
    Wang, Hui
    Liu, Yunru
    Guo, Qiaoru
    Zhang, Lingling
    Li, Jiajun
    Zhou, Wenmin
    Yan, Yanyan
    Zhou, Xinke
    Zhang, Jianye
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [27] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
  • [28] Serum Perforin Levels During the First Cycle of Anti-PD-1 Antibody Therapies in Non-Small Cell Lung Cancer
    Ota, T.
    Fukui, T.
    Nakahara, Y.
    Takeda, T.
    Uchino, J.
    Mouri, T.
    Kudo, K.
    Nakajima, S.
    Suzumura, T.
    Okabe, T.
    Hayashi, H.
    Miyatake, N.
    Nakano, Y.
    Terashima, M.
    Hasegawa, Y.
    Tsukuda, H.
    Matsui, K.
    Masuda, N.
    Fukuoka, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S455 - S455
  • [29] A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
    You, Wei
    Liu, Mei
    Miao, Ji-Dong
    Liao, Yu-Qian
    Song, Yi-Bing
    Cai, Dian-Kun
    Gao, Yang
    Peng, Hao
    JOURNAL OF CANCER, 2018, 9 (07): : 1200 - 1206
  • [30] Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer
    Ru, Chu-Hui
    Zhuang, Yan-Bing
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2018, 21 (10) : 711 - 717
12345